Skip to content

Study · Randomized controlled trial · n = 109 · 2014

10 results

A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.

Gastaldelli A, Balas B, Ratner R, Rosenstock J, Charbonnel B, Bolli GB, Boldrin M, Balena R

Diabetes, obesity & metabolism22 Aug 2013Cited by 7 (Europe PMC)

PMID23911196 (opens in a new tab)DOI10.1111/dom.12192 (opens in a new tab)PepBankPUB-23911196
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In diabetes, mean C-peptide change was lower with exenatide than taspoglutide at the lower dose.

    In plain wordsIn diabetes, average C-peptide change was lower with exenatide than low-dose taspoglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMean C-peptide change versus Taspo10
    Study

    n = 109

    Comparator
    Taspoglutide 10 mg weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mcg twice daily after 4 weeks of 5 mcg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Although changes from baseline in C-peptide were not significant within any treatment group, the mean change from baseline (both mean 0-3 h and iAUC0-3 h) was significantly increased in Taspo10 vs. Exe.
    1 context sentence
    Summary · context
    Meal tolerance tests (MTT) were performed at baseline and at week 24 in a subset of Taspo10, Taspo20 and Exe patients (n = 42, 39 and 67, respectively).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In diabetes, C-peptide incremental AUC change was lower with exenatide than taspoglutide at the lower dose.

    In plain wordsIn diabetes, cumulative C-peptide change after meals was lower with exenatide than low-dose taspoglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseC-peptide incremental AUC change versus Taspo10
    Study

    n = 109

    Comparator
    Taspoglutide 10 mg weekly
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mcg twice daily after 4 weeks of 5 mcg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Although changes from baseline in C-peptide were not significant within any treatment group, the mean change from baseline (both mean 0-3 h and iAUC0-3 h) was significantly increased in Taspo10 vs. Exe.
    1 context sentence
    Summary · context
    Meal tolerance tests (MTT) were performed at baseline and at week 24 in a subset of Taspo10, Taspo20 and Exe patients (n = 42, 39 and 67, respectively).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In diabetes, exenatide did not significantly increase mean insulin from baseline.

    In plain wordsIn diabetes, average insulin did not increase significantly during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMean insulin change
    Study

    n = 67

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mcg twice daily after 4 weeks of 5 mcg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Taspo10 and Taspo20, but not Exe, significantly increased insulin from baseline (both mean and iAUC0-3 h).
    1 context sentence
    Summary · context
    Meal tolerance tests (MTT) were performed at baseline and at week 24 in a subset of Taspo10, Taspo20 and Exe patients (n = 42, 39 and 67, respectively).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In diabetes, exenatide did not significantly increase insulin incremental AUC from baseline.

    In plain wordsIn diabetes, cumulative insulin increases after meals did not rise significantly during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeInsulin incremental AUC change
    Study

    n = 67

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mcg twice daily after 4 weeks of 5 mcg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Taspo10 and Taspo20, but not Exe, significantly increased insulin from baseline (both mean and iAUC0-3 h).
    1 context sentence
    Summary · context
    Meal tolerance tests (MTT) were performed at baseline and at week 24 in a subset of Taspo10, Taspo20 and Exe patients (n = 42, 39 and 67, respectively).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In diabetes, C-peptide changes were not significant within any group, including exenatide and taspoglutide.

    In plain wordsIn diabetes, C-peptide did not change significantly in any treatment group, including exenatide and taspoglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeC-peptide change from baseline
    Study

    n = 67

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mcg twice daily after 4 weeks of 5 mcg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Although changes from baseline in C-peptide were not significant within any treatment group, the mean change from baseline (both mean 0-3 h and iAUC0-3 h) was significantly increased in Taspo10 vs. Exe.
    1 context sentence
    Summary · context
    Meal tolerance tests (MTT) were performed at baseline and at week 24 in a subset of Taspo10, Taspo20 and Exe patients (n = 42, 39 and 67, respectively).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In diabetes, mean glucagon decreased significantly in all groups, including exenatide and taspoglutide.

    In plain wordsIn diabetes, average glucagon decreased in all treatment groups, including exenatide and taspoglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMean glucagon
    Study

    n = 67

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mcg twice daily after 4 weeks of 5 mcg · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Mean glucagon showed significant decreases in all groups.
    1 context sentence
    Summary · context
    Meal tolerance tests (MTT) were performed at baseline and at week 24 in a subset of Taspo10, Taspo20 and Exe patients (n = 42, 39 and 67, respectively).

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In diabetes, postprandial glucose time profiles showed similar patterns across exenatide and taspoglutide groups.

    In plain wordsIn diabetes, blood sugar patterns after meals were similar with exenatide and taspoglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePostprandial glucose time profile
    Study

    n = 148

    Comparator
    Taspoglutide groups
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The 2-h postprandial, mean 0-3 h and iAUC0-3 h glucose during the MTT was reduced to a similar extent in all groups and the time profile of the postprandial glucose showed a similar pattern.
    1 context sentence
    Summary · context
    Meal tolerance tests (MTT) were performed at baseline and at week 24 in a subset of Taspo10, Taspo20 and Exe patients (n = 42, 39 and 67, respectively).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 08HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, two-hour postprandial glucose during the meal test was reduced at week 24 in the exenatide group, to a similar extent as in the taspoglutide groups.

    In plain wordsIn adults with type 2 diabetes, blood sugar two hours after a meal dropped with exenatide, about as much as with taspoglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTwo-hour postprandial glucose
    Study

    n = 67

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The 2-h postprandial, mean 0-3 h and iAUC0-3 h glucose during the MTT was reduced to a similar extent in all groups and the time profile of the postprandial glucose showed a similar pattern.
    1 context sentence
    Summary · context
    Meal tolerance tests (MTT) were performed at baseline and at week 24 in a subset of Taspo10, Taspo20 and Exe patients (n = 42, 39 and 67, respectively).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 09HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, mean 0-3 h postprandial glucose during the meal test was reduced at week 24 in the exenatide group, to a similar extent as in the taspoglutide groups.

    In plain wordsIn adults with type 2 diabetes, average blood sugar after a meal dropped with exenatide, about as much as with taspoglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMean postprandial glucose
    Study

    n = 67

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The 2-h postprandial, mean 0-3 h and iAUC0-3 h glucose during the MTT was reduced to a similar extent in all groups and the time profile of the postprandial glucose showed a similar pattern.
    1 context sentence
    Summary · context
    Meal tolerance tests (MTT) were performed at baseline and at week 24 in a subset of Taspo10, Taspo20 and Exe patients (n = 42, 39 and 67, respectively).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 10HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, postprandial glucose iAUC0-3 h during the meal test was reduced at week 24 in the exenatide group, to a similar extent as in the taspoglutide groups.

    In plain wordsIn adults with type 2 diabetes, cumulative blood sugar rise after a meal dropped with exenatide, about as much as with taspoglutide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostprandial glucose incremental AUC
    Study

    n = 67

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The 2-h postprandial, mean 0-3 h and iAUC0-3 h glucose during the MTT was reduced to a similar extent in all groups and the time profile of the postprandial glucose showed a similar pattern.
    1 context sentence
    Summary · context
    Meal tolerance tests (MTT) were performed at baseline and at week 24 in a subset of Taspo10, Taspo20 and Exe patients (n = 42, 39 and 67, respectively).

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.